GAPDHP22

Across TCGA pan-cancer cohorts, GAPDHP22 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated GAPDHP22 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GAPDHP22 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GAPDHP22 expression acts as an unfavorable survival marker, although some lineages such as BLCA and CHOL show a favorable association.

LIHC, THCA, and KIRP are the cancer types where GAPDHP22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.444	0.604	<.001	105	view →
THCA	DFS	Quartile	IV	0.664	1.000	.001	80	view →
KIRP	OS	Quartile	All	0.589	0.832	<.001	47	view →
MESO	DFS	Median	III,IV	0.261	0.477	<.001	47	view →
OV	OS	Tertile	IV	0.417	0.744	.004	32	view →
BLCA	OS	Quartile	II,III,IV	0.521	0.287	.002	29	view →
CESC	DFS	Median	III,IV	0.234	0.595	.015	18	view →
CHOL	DFS	Tertile	All	0.740	0.268	.008	15	view →
LUAD	DFS	Tertile	III,IV	0.321	0.591	.008	15	view →
ACC	DFS	Tertile	All	0.502	0.820	.002	15	view →
COAD	OS	Median	IV	0.819	0.462	.004	14	view →
ESCA	OS	Median	IV	0.238	0.593	.021	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

GAPDHP22–LIHC (DFS)

Open the LIHC breakdown →